Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate

Uckert, S ; Oelke, M ; Stief, CG ; Andersson, Karl-Erik LU orcid ; Jonas, U and Hedlund, Petter LU (2006) In European Urology 49(4). p.740-745
Abstract
Objectives: With the introduction of sildenafil citrate (VIAGRA (TM)), the concept of phosphodiesterase (PDE) inhibition has gained tremendous interest in the field of urology. Cyclic nucleotide second messengers cGMP and cAMP have been assumed to be involved in the control of the normal function of the prostate. The aim of the present study was to evaluate by means of immunohistochemistry the expression and distribution of some cAMP- and cGMP-PDE isoenzymes in the prostate. Material & Methods: Cryostat sections (10 mu M) of form aldehyde-fixated tissue segments excised from the transition zone of human prostates were incubated with primary antibodies directed against the PDE isoenzymes 3, 4, 5, and 11. Then, sections were exposed to... (More)
Objectives: With the introduction of sildenafil citrate (VIAGRA (TM)), the concept of phosphodiesterase (PDE) inhibition has gained tremendous interest in the field of urology. Cyclic nucleotide second messengers cGMP and cAMP have been assumed to be involved in the control of the normal function of the prostate. The aim of the present study was to evaluate by means of immunohistochemistry the expression and distribution of some cAMP- and cGMP-PDE isoenzymes in the prostate. Material & Methods: Cryostat sections (10 mu M) of form aldehyde-fixated tissue segments excised from the transition zone of human prostates were incubated with primary antibodies directed against the PDE isoenzymes 3, 4, 5, and 11. Then, sections were exposed to either fluorescein iso-thiocyanate- (FITC) or Texas Red- (TR) labeled secondary antibodies and visualization was commenced by means of laser fluorescence microscopy. Results: TR-immunofluorescence indicating the presence of PDE4 (cAMP-PDE) was abundantly observed in the fibromuscular stroma as well as in glandular structures of the transition zone. In contrast to the distribution of PDE4, immunoactivity indicating PDE5 (cGMP-PDE) and 11 (dual substrate PDE) was mainly observed in glandular and subglandular areas. No immunostaining for PDE3 (cGMP-inhibited PDE) was detected. Conclusion: Our results confirm the presence of PDE isoenzymes 4, 5 and 11 in the transition zone of the human prostate and present evidence that these isoenzymes are not evenly distributed. These findings are in support of the hypothesis that there might be a rationale for the use of PDE inhibitors in the pharmacotherapy of BPH and LUTS. (c) 2006 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
syndrome (BPS), benign prostatic, cyclic nucleotides, prostate, phosphodiesterases
in
European Urology
volume
49
issue
4
pages
740 - 745
publisher
Elsevier
external identifiers
  • wos:000236449400024
  • scopus:33644867580
ISSN
1873-7560
DOI
10.1016/j.eururo.2005.12.050
language
English
LU publication?
yes
id
a8b27e46-7607-400d-bfcc-bbd14d880c35 (old id 414889)
date added to LUP
2016-04-01 16:08:07
date last changed
2020-12-29 03:47:06
@article{a8b27e46-7607-400d-bfcc-bbd14d880c35,
  abstract     = {Objectives: With the introduction of sildenafil citrate (VIAGRA (TM)), the concept of phosphodiesterase (PDE) inhibition has gained tremendous interest in the field of urology. Cyclic nucleotide second messengers cGMP and cAMP have been assumed to be involved in the control of the normal function of the prostate. The aim of the present study was to evaluate by means of immunohistochemistry the expression and distribution of some cAMP- and cGMP-PDE isoenzymes in the prostate. Material & Methods: Cryostat sections (10 mu M) of form aldehyde-fixated tissue segments excised from the transition zone of human prostates were incubated with primary antibodies directed against the PDE isoenzymes 3, 4, 5, and 11. Then, sections were exposed to either fluorescein iso-thiocyanate- (FITC) or Texas Red- (TR) labeled secondary antibodies and visualization was commenced by means of laser fluorescence microscopy. Results: TR-immunofluorescence indicating the presence of PDE4 (cAMP-PDE) was abundantly observed in the fibromuscular stroma as well as in glandular structures of the transition zone. In contrast to the distribution of PDE4, immunoactivity indicating PDE5 (cGMP-PDE) and 11 (dual substrate PDE) was mainly observed in glandular and subglandular areas. No immunostaining for PDE3 (cGMP-inhibited PDE) was detected. Conclusion: Our results confirm the presence of PDE isoenzymes 4, 5 and 11 in the transition zone of the human prostate and present evidence that these isoenzymes are not evenly distributed. These findings are in support of the hypothesis that there might be a rationale for the use of PDE inhibitors in the pharmacotherapy of BPH and LUTS. (c) 2006 Elsevier B.V. All rights reserved.},
  author       = {Uckert, S and Oelke, M and Stief, CG and Andersson, Karl-Erik and Jonas, U and Hedlund, Petter},
  issn         = {1873-7560},
  language     = {eng},
  number       = {4},
  pages        = {740--745},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate},
  url          = {http://dx.doi.org/10.1016/j.eururo.2005.12.050},
  doi          = {10.1016/j.eururo.2005.12.050},
  volume       = {49},
  year         = {2006},
}